Why Shares of Affimed Fell Thursday
The clinical-stage biotech focuses on immuno-oncology therapies.
Why Affimed Stock Plummeted by Over 16% Today
An analyst's downgrade brings out the bears for the European cancer treatment developer.
Billionaires Are Scooping Up These 3 Beaten-Down Biotech Stocks
This billionaire-guided hedge fund went bargain-shopping in the second quarter.
Affimed Reports Second Quarter 2022 Financial Results and Highlights Recent Operational Progress
AFM13 monotherapy: On track to report topline data of the registration-directed REDIRECT trial in the fourth quarter of 2022AFM13 combination with natural...